Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 12 results.
User Information
Export Records
  1. 1.   Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts
  2. Konaté, Mariam M; Krushkal, Julia; Li, Ming-Chung; Chen, Li; Kotliarov, Yuri; Palmisano, Alida; Pauly,Rini; Xie, Qian; Williams, P Mickey; McShane, Lisa M; Zhao, Yingdong
  3. Journal of Translational Medicine. 2024, Aug 05; 22(1): 733.
  1. 2.   Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy
  2. Sugisawa, Norihiko; Miyake, Kentaro; Higuchi, Takashi; Oshiro, Hiromichi; Zhang, Zhiying; Park, Jun Ho; Kawaguchi, Kei; Chawla, Sant P; Bouvet, Michael; Singh,Shree Ram; Unno, Michiaki; Hoffman, Robert M
  3. Anticancer research. 2019, Oct; 39(10): 5339-5344.
  1. 3.   The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model
  2. Miyake, Kentaro; Higuchi, Takashi; Oshiro, Hiromichi; Zhang, Zhiying; Sugisawa, Norihiko; Park, Jun Ho; Razmjooei, Sahar; Katsuya, Yuki; Barangi, Maryam; Li, Yunfeng; Nelson, Scott D; Murakami, Takashi; Homma, Yuki; Hiroshima, Yukihiko; Matsuyama, Ryusei; Bouvet, Michael; Chawla, Sant P; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019, SEP; 117: 109093.
  1. 4.   The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Sugisawa, Norihiko; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M.
  3. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019, Jun; 83(6): 1075-1082.
  1. 5.   Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
  2. Miyake, Kentaro; Kiyuna, Tasuku; Miyake, Masuyo; Kawaguchi, Kei; Zhang, Zhiying; Wangsiricharoen, Sintawat; Razmjooei, Sahar; Oshiro, Hiromichi; Higuchi, Takashi; Li, Yunfeng; Nelson, Scott D; Murakami, Takashi; Hiroshima, Yukihiko; Kumamoto, Takafumi; Matsuyama, Ryusei; Bouvet, Michael; Singh, Shree Ram; Chawla, Sant P; Endo, Itaru; Hoffman, Robert M
  3. Biochemical and biophysical research communications. 2019, FEB 19; 509(4): 1041-1046.
  1. 6.   The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
  2. Higuchi, Takashi; Kawaguchi, Kei; Miyake, Kentaro; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Wangsiricharoen, Sintawat; Igarashi, Kentaro; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Nelson, Scott D; Dry, Sarah M; Li, Yunfeng; Chawla, Sant P; Eilber, Frederick C; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019, Jan 04; 111: 835-840.
  1. 7.   The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel
  2. Monks, Anne; Zhao, Yingdong; Hose,Curtis; Hamed, Hossein; Krushkal, Julia; Fang, Jianwen; Sonkin, Dmitriy; Palmisano, Alida; Polley, Eric C.; Fogli, Laura K.; Konate, Mariam M.; Miller, Sarah B.; Simpson,Mel; Voth,Andrea; Li, Ming-Chung; Harris,Erik; Wu,Xiaolin; Connelly,John; Rapisarda,Annamaria; Teicher,Beverly; Simon, Richard; Doroshow, James H.
  3. Cancer research. 2018, Dec 15; 78(24): 6807-6817.
  1. 8.   Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
  2. Kawaguchi, Kei; Miyake, Kentaro; Han, Qinghong; Li, Shukuan; Tan, Yuying; Igarashi, Kentaro; Kiyuna, Tasuku; Miyake, Masuyo; Higuchi, Takashi; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Wangsiricharoen, Sintawat; Bouvet, Michael; Singh, Shree Ram; Unno, Michiaki; Hoffman, Robert M
  3. Cancer Letters. 2018, Jun 18; 432: 251-259.
  1. 9.   MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model
  2. Kawaguchi, Kei; Igarashi, Kentaro; Miyake, Kentaro; Lwin, Thinzar M; Miyake, Masuyo; Kiyuna, Tasuku; Hwang, Ho Kyoung; Murakami, Takashi; Delong, Jonathan C; Singh, Shree Ram; Clary, Bryan; Bouvet, Michael; Unno, Michiaki; Hoffman, Robert M
  3. Tissue & cell. 2018, Jun; 52: 124-128.
  1. 10.   Increased Expression of DNA Repair Genes in Invasive Human Pancreatic Cancer Cells
  2. Mathews, L. A.; Cabarcas, S. M.; Hurt, E. M.; Zhang, X. H.; Jaffee, E. M.; Farrar, W. L.
  3. Pancreas. 2011, Jul; 40(5): 730-739.
  1. 11.   Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
  2. Sei, S.; Mussio, J. K.; Yang, Q. E.; Nagashima, K.; Parchment, R. E.; Coffey, M. C.; Shoemaker, R. H.; Tomaszewski, J. E.
  3. Molecular Cancer. 2009 8 AR 47
  1. 12.   Method for analysis of nanoparticle hemolytic properties in vitro
  2. Dobrovoiskaia, M. A.; Clogston, J. D.; Neun, B. W.; Hall, J. B.; Patri, A. K.; McNeil, S. E.
  3. Nano Letters. 2008 8(8): 2180-2187.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel